Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
The company's shares were trading at $739.23, on track for their worst single-day decline in nearly four years. Copenhagen-listed rival Novo Nordisk's shares also fell 3.5%. Lilly's stock went on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback